The study patients: Inclusion criteria: All adult surgical patients who fulfilled a minimum of two SIRS criteria at the start of antibiotic therapy due to a confirmed or highly suspected bacterial infection. Main exclusion criteria: Patients who refused study consent, whose antibiotic treatment had been initiated before intensive care admission or who had therapy limitations were excluded from the study. Demographics were similar in both groups in terms of age, gender distribution, diagnoses and disease severity.
The study: Prospective, open, randomised controlled study. Patients were randomised to receive either procalcitoninguided antibiotic therapy (study group) or a standard antibiotic regimen (control). Antibiotics were selected based on confirmed or highly suspected bacterial infections for both groups. Interleukin-6, C-reactive protein (CRP), PCT, and leukocyte count were measured daily for each group. In addition, sequential organ failure assessment (SOFA) scores were calculated daily to stratify and monitor disease severity. Irrespective of the study group and at any time point, the physician in charge had the option to proceed with or adjust the antibiotic treatment if there were clinical reasons to do so.
Intervention group: (n=57, analysed=57) Antibiotic therapy in the PCT-guided group was discontinued if clinical signs and symptoms of infection improved and PCT decreased to less than 1 ng/mL, or if the PCT value was more than 1 ng/mL but had dropped to 25 to 35% of the initial value over three days.
Control group: (n=53, analysed=53). In the control group, antibiotic treatment was applied as the standard regimen over eight days. 
Procalcitonin to guide duration of antibiotic therapy in intensive care patients: a randomised prospective controlled trial
In surgical intensive care patients, monitoring of procalcitonin (PCT) is a helpful tool for guiding antibiotic treatment when compared with a standard eight day regimen. This may contribute to an optimised antibiotic regimen with beneficial effects on microbial resistance and costs in intensive care medicine.
Level of evidence: 1 + (RCT with a low risk of bias)
Appraised by: V Gopal, S Nallapareddy
Outcome

PCT-guided group Standard regimen P value
Duration of antibiotic therapy (days) 5.9 ± 1.7 7.9 ± 0.5 <0.001
Length of ICU stay (days) 15.5 ± 12.5 17.7 ± 10.1 0.046
The evidence:
6. Did they make recommendations based on the results and were they appropriate? Yes. 7. Is this study relevant to my clinical practice? Yes, if your current practice is a standard eight-day regimen of antibiotics, this study suggests that the use of procalcitonin could significantly reduce antibiotic duration. Unnecessarily prolonged antibiotic administration may lead to potential complications, such as allergic reactions, antibioticassociated colitis, and the risk of life-threatening infections from multi-resistant bacteria. However, if your current regimen is six days or less, the benefits of procalcitonin demonstrated in this study may not be applicable. 8. What level of evidence does this study represent? 1 + . 9. What grade of recommendation can I make on this result alone? B. 10.What grade of recommendation can I make when this study is considered along with other available evidence? B.
11.Should I change my practice because of these results?
Probably. This novel biomarker, procalcitonin, used to guide antibiotic therapy seems to reduce the duration of antibiotic treatment and the length of stay in the intensive care unit as a result. However, a large trial of a heterogeneous group of intensive care patients is needed.
One could also interpret the study as demonstrating that a standard antibiotic regimen of six days is preferable to eight. By adopting this change, one could gain the benefits demonstrated in this study without the cost of the procalcitonin measurement.
12.Should I audit my current practice because of these results? Yes. It is highly recommended to audit current practice of antibiotic therapy and the usefulness of this novel biomarker. 
